LBRX
insider transactionsLB PHARMACEUTICALS INC — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
+472.4K
472.4K buy · 0 sell
Net value · 365d
$10.0M
$10.0M in · $0 out
Sentiment · 365d
Net buying
100% buying · 0% selling
Open-market trades · 365d
2
472.4K buy · 0 sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Director
$0
10.0K sh
Own New
-
Grant·A
Director
$0
12.5K sh
Own New
-
Grant·A
Director
$0
10.0K sh
Own New
-
Grant·A
Director
$0
10.0K sh
Own New
-
Grant·A
Director
$0
10.0K sh
Own New
-
Grant·A
Director
$0
10.0K sh
Own New
-
Grant·A
Director
$0
10.0K sh
Own New
-
Grant·A
Director
$0
20.0K sh
Own New
-
Buy·P
$2.0M
93.9K sh · $21.17
Own New
-
Buy·P
$8.0M
378.4K sh · $21.17
Own New
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 3, 2026 | Rebecca Luse | Grant A | 10.0K | $0 |
| Jun 3, 2026 | Robert A. Lenz | Grant A | 12.5K | $0 |
| Jun 3, 2026 | Ran Nussbaum | Grant A | 10.0K | $0 |
| Jun 3, 2026 | Robert R Ruffolo | Grant A | 10.0K | $0 |
| Jun 3, 2026 | William P Kane Jr | Grant A | 10.0K | $0 |
| Jun 3, 2026 | Rekha Hemrajani | Grant A | 10.0K | $0 |
| Jun 3, 2026 | Scott J. Garland | Grant A | 10.0K | $0 |
| Mar 6, 2026 | Robert A. Lenz | Grant A | 20.0K | $0 |
| Feb 6, 2026 | Deep Track Biotechnology Master Fund, Ltd. / Deep Track Special Opportunities Fund, LP / Deep Track Capital, LP / David Kroin | Buy P | 93.9K | $2.0M |
| Feb 6, 2026 | Deep Track Biotechnology Master Fund, Ltd. / Deep Track Special Opportunities Fund, LP / Deep Track Capital, LP / David Kroin | Buy P | 378.4K | $8.0M |
About LBRX insider trading
This page tracks insider transactions for LB PHARMACEUTICALS INC (LBRX) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.